Showing results (2651-2660 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|May 4, 2023
HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trialXiaoxue Zhu, Yanhua Ding, Qian Wang, et al.Investigational New Drugs|August 18, 2020
Erlotinib and bevacizumab in elderly patients ≥75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutationsYoichiro Aoshima, Masato Karayama, Naoki Inui, et al.Investigational New Drugs|July 19, 2020
The proportion of North American cancer trials that evaluate novel targetsEli Gumnit, Aden C Feustel, Sandy Wong, et al.Investigational New Drugs|August 1, 1990
Automated measurement of transplantable solid tumors using digital electronic calipers interfaced to a microcomputerJ F Worzalla, J R Bewley, G B GrindeyInvestigational New Drugs|August 1, 1990
A phase II study of mitoxantrone in advanced gastric cancerJ A Levi, P G Gill, P PresgraveInvestigational New Drugs|August 1, 1990
Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomachD Ginn, D Kelsen, M Eisenberger, et al.Investigational New Drugs|August 1, 1990
Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Results of an Eastern Cooperative Oncology Group study (EST 2685)H Hochster, M Hunt, M Green, et al.Investigational New Drugs|June 20, 2012
A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancersA F Baker, K N Adab, N Raghunand, et al.Investigational New Drugs|July 6, 2012
Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomasTanja Trarbach, Marta Przyborek, Norbert Schleucher, et al.Investigational New Drugs|March 10, 2015
Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumorsC S Higano, J Berlin, M Gordon, et al.Pageof 372